A socially oriented non-financial development institution and a major organizer of nationwide and international conventions; exhibitions; and business, public, youth, sporting, and cultural events.

The Roscongress Foundation is a socially oriented non-financial development institution and a major organizer of nationwide and international conventions; exhibitions; and business, public, youth, sporting, and cultural events. It was established in pursuance of a decision by the President of the Russian Federation.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5,000 people working in Russia and abroad.

The Foundation works alongside various UN departments and other international organizations, and is building multi-format cooperation with 173 economic partners, including industrialists’ and entrepreneurs’ unions, financial, trade, and business associations from 78 countries worldwide, and 179 Russian public organizations, federal and legislative agencies, and federal subjects.

The Roscongress Foundation has Telegram channels in Russian t.me/Roscongress, English – t.me/RoscongressDirect, and Spanish t.me/RoscongressEsp. Official website and Information and Analytical System of the Roscongress Foundation: roscongress.org.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Victor Fisenko

Victor Fisenko

First Deputy Minister of Health of the Russian Federation
Quotes
16.06.2022
SPIEF 2022
Replacing Imports with Domestic Alternatives in Healthcare: New Areas of Growth
We took this path [of simplifying clinical trials and medication licensing, – Ed.] in 2020–2021, during the pandemic. We have proved that we can amend the legislation fast.  <…> All procedures related to simplification of clinical trials and licensing will be used under the present circumstances as well
16.06.2022
SPIEF 2022
Replacing Imports with Domestic Alternatives in Healthcare: New Areas of Growth
The brands like ‘Made in the Eurasian Economic Union’ and ‘Made in Russia’ must get people’s trust. This is our common objective that Russian manufacturers share with us. They should launch a campaign to raise the trust level in domestically produced medications. <…> Patients do not just buy whatever they want – it is doctors who prescribe things
16.06.2022
SPIEF 2022
Replacing Imports with Domestic Alternatives in Healthcare: New Areas of Growth
We have a list of essential [medications, – Ed.] made up of 809 items. The Russian pharmaceutical industry is capable of producing about 80% of them. It is nearly 650 international unpatented medications. <…> Do we need to strive for replacing 100% of components? Probably, not a single country in the world is fully independent in everything. We can do some things on our own and other things we will do together with the Eurasian Economic Union countries or with our strategic partners
15.06.2022
SPIEF 2022
The Economics of Drug Supply: How to Balance Supply and Demand
We have made fairly rapid steps. In previous years, there were long discussions about distance selling. The practice of distance selling has begun, and more than five hundred positive decisions have been issued to date, if I am not mistaken. […] We are now working on an experimental legal regime for the distance selling of prescription drugs as well. This is the next step toward improving accessibility. At the end of 2021, we practically equalized the medical licence with the pharmacy licence for territorially separate facilities, i.e. for urgent care centres and outpatient clinics in those localities where we do not have pharmaceutical organizations. Almost all regions have licensed all their urgent care centres falling under this category during the first quarter of 2022
15.06.2022
SPIEF 2022
The Economics of Drug Supply: How to Balance Supply and Demand
We can argue about the system of state regulation of prices for medicines and criticize it at length, but one of the functions of state regulation is price containment. We also use this system to mitigate social risks, because drug affordability is made up of territorial, assortment, and pricing availability
15.06.2022
SPIEF 2022
The Economics of Drug Supply: How to Balance Supply and Demand
Our main tool is the use of data. We have to be very precise about the needs of the healthcare system and our future forecasting [...] We are now moving towards an experiment to create a unified register with information about prescriptions and the dispensation of medicines. This will enable us to see and assess both current and prospective needs, allowing us to take into account both events that have already taken place as well as clinical guidelines.  We have a system for monitoring the movement of medicines which allows us to rule out overspending and the emergence of substandard products. All together, these tools will give us a complete picture and an understanding of the true needs of the healthcare system in the near future
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
We can say that one of the advantages of our products is the price – in the domestic market, in the EAEU market and beyond. We believe that the domestic market and the EAEU one, including our strategic partners, are the most promising for us. It does not only concern generics, but biotech products as well
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
Now both federal authorities and the industry face the need for a publicity campaign that will help doctors and patients put their trust in medications. This is why the brands ‘Made in the EAEU’ and ‘Made in Russia’ need to become a quality seal that both the medical community and patients will trust. The numbers on efficiency, safety and quality that we see fully confirm my words
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
Now we are facing new challenges, so the federal authorities and our industry are busy looking for new solutions, such as coming up with new logistics to supply substances, excipients, and equipment – everything needed for producing medications and for further development
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
I believe we have the potential for not just import substitution, but for creating new molecules. Pharma 2030 and the new initiative called ‘Medical science for people’ will contribute to that. There are several promising developments among the victories of the Ministry of Health. <…> We believe that our mission is getting over this ‘Death Valley’, while these initiatives may be part of it. It means intercommunication and a fast track from invention to industry – to the actual market,
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
Forum materials mentioned the outlook for the ‘Made in the EAEU’ brand. I would like to say that the EAEU norms are aligned with international rules. It concerns efficiency, quality, and safety. This is why the ‘Made in the EAEU’ brand is very promising, because these are the medications, the products that indeed comply with all the requirements. When it comes to our fast tracks, we have learned to introduce medical products to the market without compromising the quality. This is why the quality control system created earlier has proven its efficiency over the recent years. <…> Our country now boasts only high-quality, efficient, and safe medications,
15.06.2022
SPIEF 2022
Export Potential: EAEU and the Global Market
We see that our domestic industry is capable of producing almost the full range of essential medications: about 80% out of 809 items can be made in our country with a different rate of localization. We have learned to work and introduce medical products to the market. You probably remember decree 441, which upset many of our foreign partners and made many people in country blame us, calling it an experiment, and so on. However, we see that a lot of countries – almost all the countries – have chosen the fast-track way for introducing medications to the market
03.09.2021
EEF 2021
Health Technologies
One of the pathways we can traverse involves the creation of diagnostic test systems to identify diseases. This is likely something we want to do in the near future. We are currently working on an initiative that would form part of the front-end system – medical science for people. One of the elements of this would be the creation of genetic passports. This would apply to newborns, and to all our citizens. It would make it possible to adopt a flexible and effective approach to managing patients’ health. <...> As part of a federal project to create an integrated digital space, we are fulfilling objectives related to having functioning medical information systems in the regions. If there are several of them in one region, they should be integrated via a bus and be interconnected. An archive of medical images is being created. When running tests, doctors can upload them onto the archive, and other doctors with access can look at them
03.09.2021
EEF 2021
Health Technologies
When we write things on paper, and then begin to fill out a medical record in a completely unstructured way, using Word, pasting in some medical notes, it goes without saying that this is not digital transformation at all. <...> A system like this is of little help, and it just means a pile of paper has become a pile of unstructured paperwork. This is hardly capitalizing on information technology. <...> A medical organization needs to create a set of structured primary data which can then be lifted and analysed. And it needs to implement solutions accordingly
03.09.2021
EEF 2021
Health Technologies
The digital sphere and science are the two main drivers of development in the healthcare system. Our strategic target is to move away from very early disease diagnosis, and towards prevention. Genetic research and technology will of course come to our aid in this area. We need to traverse a path whereby we will be able to identify genetic markers, predictors of disease, and manage them. <...> Our objective is the soft integration of digital technologies into the medical care system. Under no circumstances do we view this as a substitution for traditional medicine – a substitution for seeing your general practitioner, having consultations, and so on. Digital technologies are rather a powerful aid in the medical care system, and we have pinned great hopes on them
02.09.2021
EEF 2021
Partnership Against the Pandemic: Anti-Crisis Strategies in Medicine
We also need to acknowledge the model of healthcare provision. We took the route of putting together instructional guidelines, and in the initial months we summarized all global best practices with the help of leading specialists from outside the ministry. We have put together everything we need in order to issue guidelines that will help doctors throughout the country deal with this threat comprehensively. That includes the use of medicines, medical devices and patient treatment methods
02.09.2021
EEF 2021
Partnership Against the Pandemic: Anti-Crisis Strategies in Medicine
We have been through it all over the last year and a half. You could say we have witness a crisis in the traditional management system. We already understood very well that the classic models weren’t working at the beginning of 2020